Antibodies in Discovery and Development, London
Event Start date: 28 Mar 2007
Event End date: 29 Mar 2007
A two-day international conference on 28th & 29th March 2007 London UK.

ACI's inaugural Antibodies in Discovery and Development Conference, taking place in March 2007 in Central London, UK, will consider the key role of antibody technologies within discovery and development, addressing the latest challenges and developments within this rapidly changing sector.

Please call Melanie Mulazzi on +44 20 7368 1654 or Email her at mmulazzi@acius.net if you want some additional information or if you want to register.

The conference will bring together industry leaders working in the research and development of antibody therapeutics, alongside discovery and development professionals seeking an update on the key issues, to address the principal strategic business, IP and regulatory issues involved in planning investment in and growth of your antibody pipeline.

The programme will focus on key topics including:

  • The current marketplace and future trends
  • Commercialising antibodies - partnership and collaboration agreements; making the best deal, managing and maintaining relationships
  • Regulatory implications - biosimilar approvals, regulatory impact on future products and manufacturing
  • Intellectual property - finding a way around patent challenges, protecting your antibodies
  • ROI on antibody investments - ensuring profitability of antibody therapeutics
  • Strategies to overcome problems in delivery and manufacture

    Who should attend?

    Attendees will be from medium to large pharmaceutical and biotechnology companies worldwide and will include VPs, Directors and Managers/Senior Scientists of:
    R&D, Biopharmaceuticals, Biopharmaceutical Development and Research, Antibody Development, Biology/Biologics, Cell Science/Therapeutics, Biotherapeutics, Biotherapeutic Development and Research, Bioprocess Research, Immunology, Inflammatory Oncology, CNS and Infectious Diseases, Biotechnology, Regulatory Affairs, IP and Strategic Alliances and Partnerships

    Who will be speaking?

    Our expert panel of speakers comprises biopharmaceutical research and development leaders from industry, alongside regulatory and intellectual property specialists, giving you an insight into the key business and strategic challenges in maintaining and expanding the efficiency and profitability of your antibody pipeline and building the business case to increase or make an initial investment into the antibody therapeutic market.

    Speakers include:

    Dr. Hanno Wild, Senior Vice President, Discovery Europe, Pharma Global Drug Discovery, Bayer Healthcare AG
    Dr Wiebe Olijve, Vice President, Research, Organon
    Dr Dee Athwal, Director, Research Licensing and Business Development, UCB-Celltech Group
    Dr. Melvyn Little, CSO, Affimed Therapeutics AG
    Dr. Jan ter Meulen, Executive Director, Infectious Diseases, Crucell
    Dr. Tim Sparey, Associate Director, Licensing & External Research Europe, Merck, Sharp & Dohme
    Dr. Josep Lamarca, Senior Director, Corporate Licensing, Almirall Prodesfarma
    Dr. Neil Weir, Vice President Research, Antibody Centre, UCB-Celltech
    Dr. Margi McLoughlin, Associate Director, Strategic Alliances, Pfizer Inc.
    Klaas Bisschop, Partner and Head, Pharmaceuticals, IP and IT, Lovells, Amsterdam
    Dr Richard Turner, Director, Regulatory Affairs (UK), ERA Consulting (UK) Ltd.

    With Thanks to our Supporting Organisations
    Pharma and Healthcare Insight
    European Biotech News
    TheScientificWorld Limited
    WOCP
    Human Antibodies
    Royal Society Of Chemistry
    European Biopharmaceutical Review
    Future-Drug
    GenomicsProteomics.com
    HTSreening.net
    Next Generation Pharmaceutical
    Cancer Drug News



    •  Email to author
    Article Id: 227195
    Event Start date: 28 Mar 2007
    Event End date: 29 Mar 2007